When to Use Finerenone
Initiate finerenone in adults with type 2 diabetes and chronic kidney disease who have persistent albuminuria (>30 mg/g) despite maximally tolerated RAS inhibitor therapy, eGFR >25 mL/min/1.73 m², and serum potassium ≤4.8 mmol/L. 1
Patient Selection Criteria
Finerenone is most appropriate for patients at high risk of CKD progression and cardiovascular events, specifically those with:
- Type 2 diabetes with CKD
- eGFR >25 mL/min/1.73 m² (do not initiate below this threshold)
- Persistent albuminuria (UACR >30 mg/g or >3 mg/mmol) despite maximum tolerated dose of ACE inhibitor or ARB
- Serum potassium ≤4.8 mmol/L at baseline (consistently normal, not just a single measurement) 1
The KDIGO 2024 guidelines provide a Grade 2A recommendation for nonsteroidal MRA use in this population, emphasizing that these patients demonstrate residual risk despite standard-of-care therapies 1.
Dosing Algorithm
Initial dose selection based on eGFR:
- eGFR 25-59 mL/min/1.73 m²: Start finerenone 10 mg once daily
- eGFR ≥60 mL/min/1.73 m²: Start finerenone 20 mg once daily 1
Dose titration strategy:
- Monitor potassium at 1 month after initiation
- If potassium remains ≤4.8 mmol/L and patient started on 10 mg, increase to 20 mg daily
- Continue monitoring potassium every 4 months thereafter 1
Integration with Other Therapies
Finerenone may be added to existing therapy with both RAS inhibitors and SGLT2 inhibitors 1. This triple therapy approach is supported by the guidelines, with Practice Point 3.8.2 explicitly stating that nonsteroidal MRA can be added to RASi and SGLT2i for treatment of T2D and CKD 1. Recent evidence from the CONFIDENCE trial demonstrates that simultaneous initiation of finerenone with empagliflozin produces greater albuminuria reduction than either agent alone, with no unexpected safety concerns 2.
The treatment sequence should prioritize:
- First: Maximize RAS inhibitor (ACE inhibitor or ARB) dose 3
- Second: Add SGLT2 inhibitor (eGFR ≥20 mL/min/1.73 m²) 1
- Third: Add finerenone if albuminuria persists 1
Potassium Management Protocol
Critical safety consideration: The most important side effect is hyperkalemia, which increases as renal function declines 4.
Management based on potassium levels:
| Potassium Level | Action |
|---|---|
| ≤4.8 mmol/L | Initiate or continue finerenone; monitor every 4 months |
| 4.9-5.5 mmol/L | Continue current dose; monitor every 4 months |
| >5.5 mmol/L | Hold finerenone; adjust diet/medications; recheck potassium; consider reinitiation when ≤5.0 mmol/L |
Key principle: Select patients with consistently normal serum potassium, not just a single measurement. Be aware of potassium measurement variability including diurnal and seasonal variation 1.
Common Pitfalls to Avoid
Don't wait too long to initiate: Starting treatment early when eGFR is maintained reduces side effects and provides stronger clinical benefit. The FIDELITY analysis demonstrates that clinical effects are stronger with earlier CKD stage initiation 4.
Don't discontinue prematurely for mild hyperkalemia: Potassium levels of 4.9-5.5 mmol/L warrant continued therapy with monitoring, not immediate discontinuation. Consider dietary modifications and concomitant medication adjustments before stopping 1.
Don't use with other MRAs: Do not combine finerenone with steroidal MRAs (spironolactone, eplerenone) for CKD/diabetes indication 1.
Don't forget baseline optimization: Ensure patients are on maximally tolerated RAS inhibitor doses before adding finerenone 3, 1.
Real-World Implementation
Real-world data from the FINE-REAL study shows that 81% of patients initiate at 10 mg daily, with 26% subsequently increasing to 20 mg 5. Finerenone was continuously administered for up to 1 year in 85% of participants, with discontinuation due to hyperkalemia in only 1% 5. This demonstrates excellent tolerability when proper patient selection and monitoring protocols are followed.
The incidence of hyperkalemia leading to hospitalization or discontinuation is low (1.2% discontinuation rate) when guidelines are followed 6, 7.